Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 10499642)

1.

Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs.

Cozzi PJ, Bajorin DF, Tong W, Nguyen H, Scott J, Heston WD, Dalbagni G.

Clin Cancer Res. 1999 Sep;5(9):2629-37.

2.

Experimental study on the toxicity and the local and systemic tolerability of gemcitabine after topical treatment of the rabbit bladder.

Matera M, Costantino G, Clementi G, Lempereur L, Vasta D, Vasquez E.

Oncol Rep. 2004 Jun;11(6):1145-51.

PMID:
15138548
3.

Pharmacokinetics of intravesical gemcitabine: a preclinical study in pigs.

Witjes JA, Vriesema JL, van der Heijden AG, Peters GJ, Schalken JA.

Eur Urol. 2003 Nov;44(5):615-9.

PMID:
14572765
4.

Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study.

Laufer M, Ramalingam S, Schoenberg MP, Haisfield-Wolf ME, Zuhowski EG, Trueheart IN, Eisenberger MA, Nativ O, Egorin MJ.

J Clin Oncol. 2003 Feb 15;21(4):697-703.

PMID:
12586808
5.

Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study.

Mattioli F, Curotto A, Manfredi V, Gosmar M, Garbero C, Ambruosi C, Carmignani G, Martelli A.

Anticancer Res. 2005 May-Jun;25(3c):2493-6.

6.

Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation.

De Berardinis E, Antonini G, Peters GJ, Loves WJ, Van der Born K, Codacci-Pisanelli G, Di Silverio F.

BJU Int. 2004 Mar;93(4):491-4.

PMID:
15008715
7.

Intravesical gemcitabine: a phase 1 and pharmacokinetic study.

Witjes JA, van der Heijden AG, Vriesema JL, Peters GJ, Laan A, Schalken JA.

Eur Urol. 2004 Feb;45(2):182-6.

PMID:
14734004
8.

Microemulsions for intravesical delivery of gemcitabine.

Tsai YH, Hsieh YH, Huang YB, Chang JS, Huang CT, Wu PC.

Chem Pharm Bull (Tokyo). 2010 Nov;58(11):1461-5.

9.

Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.

Shelley MD, Jones G, Cleves A, Wilt TJ, Mason MD, Kynaston HG.

BJU Int. 2012 Feb;109(4):496-505. doi: 10.1111/j.1464-410X.2011.10880.x. Review.

PMID:
22313502
10.

Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guérin therapy.

Bassi P, De Marco V, Tavolini IM, Longo F, Pinto F, Zucchetti M, Crucitta E, Marini L, Dal Moro F.

Urol Int. 2005;75(4):309-13.

PMID:
16327296
11.

Systemic absorption and pharmacokinetics of single-dose intravesical gemcitabine after transurethral resection of the bladder in non-muscle-invasive bladder cancer.

Maffezzini M, Campodonico F, Puntoni M, Martelli A, Mattioli F.

Urology. 2009 Nov;74(5):1078-83. doi: 10.1016/j.urology.2009.05.094. Epub 2009 Sep 20.

PMID:
19773039
12.

Antineoplastic effect of gemcitabine in an animal model of superficial bladder cancer.

Nativ O, Dalal E, Laufer M, Sabo E, Aronson M.

Urology. 2004 Oct;64(4):845-8.

PMID:
15491745
13.
14.

Pharmacokinetics and toxicity of an early single intravesical instillation of gemcitabine after endoscopic resection of superficial bladder cancer.

Campodonico F, Mattioli F, Manfredi V, Capponi G, Pasquini P, Martelli A, Maffezzini M.

Anticancer Res. 2007 Mar-Apr;27(2):1179-83.

15.

Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma.

Paroni R, Salonia A, Lev A, Da Pozzo LF, Cighetti G, Montorsi F, Rigatti P, Colombo R.

Br J Clin Pharmacol. 2001 Sep;52(3):273-8.

16.

Actual experience and future development of gemcitabine in superficial bladder cancer.

Gontero P, Frea B.

Ann Oncol. 2006 May;17 Suppl 5:v123-8. Review.

17.

Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion.

Freise KJ, Martín-Jiménez T.

J Vet Pharmacol Ther. 2006 Apr;29(2):147-52.

PMID:
16515669
18.
19.

Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions.

Serretta V, Galuffo A, Pavone C, Allegro R, Pavone-MacAluso M.

Urology. 2005 Jan;65(1):65-9.

PMID:
15667865
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk